Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Comparison Of Mmp-2, Mmp-9, Cox-2, And Pgp Expression In Feline Injection-site And Feline Noninjection-site Sarcomas-pilot Study.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Comparison Of Mmp-2, Mmp-9, Cox-2, And Pgp Expression In Feline Injection-site And Feline Noninjection-site Sarcomas-pilot Study.

Related Experiment Video

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Comparison of MMP-2, MMP-9, COX-2, and PGP Expression in Feline Injection-Site and Feline Noninjection-Site Sarcomas-Pilot Study.

Agata Wojtkowska1, Anna Małek1, Sławomir Giziński2

  • 1Department of Small Animal Diseases with Clinic, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.

Animals : an Open Access Journal From MDPI
|July 27, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Feline injection-site sarcomas (FISS) show higher expression of COX-2, MMP-9, and PGP compared to non-FISS. This study reveals distinct immunohistochemical profiles for these feline tumors.

Keywords:
P-glycoproteincyclooxygenase-2feline injection-site sarcomafibrosarcoma

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.4K

Related Experiment Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.4K

Area of Science:

  • Veterinary Pathology
  • Oncology
  • Immunohistochemistry

Background:

  • Feline injection-site sarcomas (FISS) are aggressive tumors often linked to vaccinations.
  • Feline non-injection-site sarcomas (non-FISS) are less common and can occur anywhere.
  • Understanding protein expression differences is crucial for feline sarcoma research.

Purpose of the Study:

  • To compare the expression of MMP-2, MMP-9, COX-2, and PGP in FISS and non-FISS.
  • To correlate protein expression with mitotic count in feline sarcomas.
  • To characterize the immunohistochemical features of FISS and non-FISS.

Main Methods:

  • Immunohistochemistry was used to analyze eleven FISS and eight non-FISS samples.
  • Expression levels of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2), and P-glycoprotein (PGP) were assessed.
immunohistochemistry
matrix metalloprotease
  • Spearman rank correlation analysis was performed.

    • Main Results:

    • High positivity rates were observed for COX-2 (80.4%), MMP-9 (90.2%), and PGP (100%).
    • COX-2, MMP-9, and PGP expression were significantly higher in FISS than in non-FISS (p ≤ 0.001 for COX-2, p ≤ 0.05 for MMP-9 and PGP).
    • Correlations included moderate negative between COX-2 and MMP-9 in FISS (r = -0.52), and strong negative between COX-2 and PGP in non-FISS (r = -0.81).

    Conclusions:

    • The study established distinct immunohistochemical profiles for FISS and non-FISS.
    • Elevated expression of COX-2, MMP-9, and PGP in FISS suggests their involvement in tumor development.
    • Findings contribute to a better understanding of feline sarcoma biology and potential therapeutic targets.